Sinovac Biotech Ltd (SVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -198,836 | 40,656 | -120,858 | 88,131 | 14,458,910 |
| Depreciation Amortization | 98,777 | 111,279 | 158,444 | 154,848 | 84,629 |
| Income taxes - deferred | -89,911 | -56,406 | -17,409 | -83,010 | 265,096 |
| Accounts receivable | 24,267 | 87,733 | 50,409 | 289,600 | -710,355 |
| Other Working Capital | -376,650 | -123,459 | 237,903 | -1,081,188 | 460,615 |
| Other Operating Activity | 30,169 | -116,694 | -169,844 | -139,126 | 793,645 |
| Operating Cash Flow | $-512,184 | $-56,891 | $138,645 | $-770,745 | $15,352,540 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | N/A | -2,538,168 | N/A | N/A |
| PPE Investments | -48,508 | -95,800 | -156,112 | -393,192 | -719,651 |
| Net Acquisitions | -13,967 | -100,195 | N/A | 114,352 | N/A |
| Purchase Of Investment | -6,223,708 | -4,911,892 | N/A | -11,763,900 | -8,840,274 |
| Sale Of Investment | 10,673,090 | 5,594,972 | N/A | 6,327,521 | 6,567,491 |
| Purchase Sale Intangibles | -203 | -1,627 | -40 | -9,568 | -154 |
| Other Investing Activity | 1,263 | -30,726 | -4,771 | -45,251 | -31,140 |
| Investing Cash Flow | $4,388,170 | $456,359 | $-2,699,051 | $-5,760,470 | $-3,023,574 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 318,401 | 204,775 | 243,395 | 151 | 13,511 |
| Debt Issued | N/A | N/A | N/A | N/A | 7,119 |
| Debt Repayment | N/A | N/A | -4,237 | -1,486 | -13,332 |
| Common Stock Issued | N/A | N/A | 676 | N/A | 1,033 |
| Dividend Paid | -3,534,344 | -946,997 | -328,080 | -263,171 | -1,875,892 |
| Other Financing Activity | -218,763 | -81,728 | -308 | 23,107 | -29,119 |
| Financing Cash Flow | $-3,434,706 | $-823,950 | $-88,554 | $-241,399 | $-1,896,680 |
| Exchange Rate Effect | 112,932 | -102,423 | -108,846 | -560,769 | 137,269 |
| Beginning Cash Position | 602,217 | 1,129,122 | 3,886,928 | 11,619,760 | 1,050,204 |
| End Cash Position | 1,156,429 | 602,217 | 1,129,122 | 4,286,377 | 11,619,760 |
| Net Cash Flow | $554,212 | $-526,905 | $-2,757,806 | $-7,333,383 | $10,569,560 |
| Free Cash Flow | |||||
| Operating Cash Flow | -512,184 | -56,891 | 138,645 | -770,745 | 15,352,540 |
| Capital Expenditure | -48,917 | -95,960 | -156,165 | -393,800 | -719,823 |
| Free Cash Flow | -561,101 | -152,851 | -17,520 | -1,164,545 | 14,632,717 |